World Leading Innovators In

Wearable Technology

For the Treatment of Nausea and Vomiting

Reliefband® Technologies is a world-leader in neuromodulation and wearable technology. We build hardware products and software platforms powered by science, data and clinical research for the treatment of nausea and vomiting.

Using highly effective and responsive technology, our digital wearable devices are clinically tested, FDA cleared and endorsed by the medical profession. Easy-to-use, comfortable and adjustable, they bring a new dimension to treatment by putting people back in control.

Partners

For access to our Partners portal please enter your registration details below.

For more information on how to become a Partner or Distributor of Reliefband Technologies products please contact us on 877-735-2263.

Username (required)

Password(required)

wilburWilbur H. Gantz, III

Chairman of the Board

Wilbur is the Executive Chairman of Naurex, Inc., a biopharmaceutical company, and the President of PathoCapital LLC, a private investment firm. Mr. Gantz was formerly Chairman and Chief Executive Officer of Ovation Pharmaceuticals, Inc., a position assumed in 2002. Previously he served as Chairman and Chief Executive Officer of PathoGenesis Corporation and as President of Baxter International Inc. Mr. Gantz serves as a director of Adams Street Partners and is a trustee of the Field Museum.

Nicholas (Nick) U. Spring

Director and CEO

Nicholas is an experienced CEO, successful executive and entrepreneur with a track record of company startups, development and exits in the OTC and Rx Pharmaceutical markets. Topaz Pharmaceuticals Inc., the company that he founded in 2005, was acquired by Sanofi Pasteur in 2011. He personally led Topaz through multiple rounds of financing, R&D (pre-clinical to FDA submission) as CEO & President and Board Member. The FDA approved Sklice®, the product that he founded the company upon, on Feb 7, 2012 – a major achievement for a small startup company. Nick has worked closely with digital healthcare companies as well as middle to big Pharma companies advising them at the highest level on business strategies and life cycle management. Prior to that he enjoyed a global career at Merck as a senior manager in many countries worldwide. Nick is also a Business Adviser with the Science Center of Philadelphia’s QED program for innovation, an Adjunct Professor of Pharmaceutical and Healthcare business at the University of Sciences, Philadelphia and was recently elected to the Commercialization Advisory Board of Penn State College of Medicine.

David N Jonas

Director

David is the Founder, President and Chief Executive Officer of JVC Investment Partners LLC, since October 2000, a firm that provides private investment and strategic support to early stage and middle market businesses in the healthcare space. Mr. Jonas founded PHC in 2003 and was its Chairman and Chief Executive Officer until January 2014 and  continue to be a member of its  board of directors. Prior to founding JVC Investment Partners and  PharMEDium, Mr. Jonas held  a number of senior management  position with Baxter  including the  co-founder and COO/CFO  of  Renal Therapy Services Worldwide Inc. a subsidiary of Baxter International Inc. Mr. Jonas served on boards of various  privately held companies and non-for-profit organizations including the  Chicago Medical School, Gore-Bronson Bancorp, Healthcare Venture Fund, Medica Venture Fund, IBAX Healthcare Systems. Mr Jonas received BS degree  in Finance and MBA from Roosevelt University. Mr. Jonas business management experience, spanning more than 35 years, includes extensive strategic and operational experience in product development, manufacturing, sales and distribution of critical healthcare products and services.

Cameron Durrant MD, MBA

Director

Cameron is an accomplished pharmaceuticals and biotech entrepreneur, marketer, financing, business and corporate development professional with a strong medical base. He has served as chairman and director on the boards of numerous companies, and operated as CEO or interim CEO for four venture-backed companies. In other assignments, he has been a senior executive at Johnson and Johnson, Pharmacia Corporation, GSK and Merck,. He has served as the founding investor, Chairman and CEO of publicly-traded PediaRX (acquired by Apricus Biosciences, a NASDAQ company), Executive Chairman of publicly traded Anavez, CEO of PediaMed Pharmaceuticals (acquired by Connetics Corporation and also Tiber Labs), Chairman of Pressure Point (now with an FDA-cleared, marketed medical device), founding director of Bexion Pharmaceuticals (now with a Phase I, novel lipid/protein nanotech oncology therapeutic/imaging agent), board member of Topaz Pharmaceuticals (acquired by Sanofi-Pasteur), board member of PDS Biotechnology Corporation and founder investor in Prism Pharmaceuticals (acquired by Baxter). He has been involved in 5 exits, ranging from a 2-9x return. Dr. Durrant has been an advisor to Microsoft Corporation, Aprecia Pharmaceuticals, Pilgrim Software (acquired by a private equity group), PathXL and Saxa Private Equity Partners. He has also been involved in creating companies around targeted early-stage technologies with Cincinnati Children’s Hospital and assisted numerous private equity groups in their diligence efforts, leading to successful deal closure. He has raised significant capital in VC, private equity, angel and high net worth financings.

Bruce Carbonari

Director 

Bruce is the retired Chairman and CEO of Fortune Brands, the $7 billion consumer products company. Today, he invests and sits on boards of high potential startups and mid cap private equity companies who are focused on strategic growth. Bruce is also currently the Lead Director and Chairman of the Governance and Nominating committee of RPM International, Inc. During his 20 plus years at Fortune Brands, Bruce held many leadership positions starting with being President and CEO of Moen in 1989. Under his leadership, Moen more the quadrupled it sales to over $1 billion dollars and became the number one brand in the North America and the most profitable business within Fortune Brands. By 2000, he was the President and CEO of the Fortune Brands Home and Security Business that more than doubled to over $4 billion in sales. Being promoted to President and COO of Fortune Brands in 2005, he led the 5-year transformation of the spirits business from an underperforming business unit to becoming the fastest growing spirits business in the world. And finally under his chairmanship at Fortune Brands, he lead the split up of Fortune Brands creating significant shareholder value. Prior to joining Fortune Brands, he held positions at Forstmann Little, Stanadyne and Price Waterhouse. Bruce has been honored and inducted into numerous business hall of fames and currently involved in numerous leadership position in non-profit organizations.

Jeffrey H. Nicholas, Esq.

General Counsel and Secretary 

Jeffrey is a partner of the law firm of Fox Rothschild LLP and Chair of the Firm’s Corporate Department, focuses his practice on capital formation, public company reporting, compliance and transactions, corporate governance, and M&A. This includes working with Boards of Directors and entrepreneurs at each point in the life cycle of business formation, growth and exit transactions. Jeff serves many clients as general counsel where he combines his broad legal experience with a practical business sense. Jeff is a member of Fox Rothschild’s Executive Committee and is managing partner of the firm’s 30 lawyer Bucks County office. Jeff serves as managing director of Delaware Crossing Investor Group (www.delawarecrossing.org), an angel investor network conceived of and managed with two Fox Rothschild colleagues. Jeff is a member of the Executive Committee of Heritage Conservancy, a leading regional land preservation group. He is also active in Fisherman’s Mark, a not-for-profit which provides assistance to the needy in the Lawrenceville, NJ area. Jeff has served in a number of other leadership roles at Fox Rothschild, including Chair of the Emerging Companies Practice Group and Chair of Public Companies Practice Group.